@article{07487c88bb5b4e3587639cc7a229eec9,
title = "Palmitoylethanolamide (PEA) in the treatment of neuropathic pain: a case study",
abstract = "Background: Neuropathic pain is a condition caused by a lesion or disease of the somatosensory nervous system. It may present as debilitating pain with a sensation of burning and electric-like symptoms and is often difficult to manage effectively. Although pharmacological medications are the first line of treatment, multidisciplinary teams are sometimes required to provide appropriate treatment to improve quality of life and overall wellbeing. Aim: The aim of this study is to present a case of post herpetic neuralgia relieved successfully by the compound palmitoylethanolamide (PEA) – a natural alternative to pharmacological pain relief. Methods: We present the case of a 67 year-old male with ongoing post-herpetic neuralgia, over a 3-year period, as a result of complications from shingles (herpes zoster). Previous studies on the relationship between PEA and neuropathy were reviewed, with an attempt to discuss the possible underlying mechanism of PEA on neuropathic pain. Results: PEA demonstrated effective pain relief within 48 hours at an administered daily dose of 900 mg (10 mg/kg). Conclusions: PEA may offer a valid nutraceutical treatment for practitioners. {\textcopyright} The Author(s) 2021.",
keywords = "analgesic, CB2, neuropathy, palmitoylathenolamide, PEA, shingles, amide, ethanolamine derivative, palmidrol, palmitic acid derivative, aged, case report, complication, herpes zoster, human, male, neuralgia, pathology, pea, quality of life, Aged, Amides, Ethanolamines, Herpes Zoster, Humans, Male, Neuralgia, Palmitic Acids, Peas, Quality of Life",
author = "D. Kamper",
note = "Export Date: 12 July 2022 Correspondence Address: Kamper, D.; Western Sydney University, Australia; email: dkamper@torrens.edu.au Chemicals/CAS: amide, 17655-31-1; palmidrol, 544-31-0; Amides; Ethanolamines; palmidrol; Palmitic Acids Funding text 1: The author received no financial support for the research, authorship, and/or publication of this article. References: Capasso, R., Orlando, P., Pagano, E., Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB 1 receptors and TRPV 1 channels (2014) British Journal of Pharmacology, 171 (17), pp. 4026-4037; Carta, G., Murru, E., Banni, S., Palmitic acid: physiological role, metabolism and nutritional implications (2017) Frontiers in Physiology, 8, p. 902; Cohen, S.P., Mao, J., Neuropathic pain: mechanisms and their clinical implications (2014) British Medical Journal, 348, p. f7656; Das, L., Bhaumik, E., Raychaudhuri, U., Role of nutraceuticals in human health (2012) Journal of Food Science and Technology, 49 (2), pp. 173-183; Elokely, K., Velisetty, P., Delemotte, L., Understanding TRPV1 activation by ligands: insights from the binding modes of capsaicin and resiniferatoxin (2016) Proceedings of the National Academy of Sciences of the United States of America, 113 (2), pp. E137-E145; Gabrielsson, L., Mattsson, S., Fowler, C.J., Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy (2016) British Journal of Clinical Pharmacology, 82 (4), pp. 932-942; Gupta, K., Harvima, I.T., Mast cell-neural interactions contribute to pain and itch (2018) Immunological Reviews, 282 (1), pp. 168-187; Ho, W.S., Barrett, D.A., Randall, M.D., {\textquoteleft}Entourage{\textquoteright} effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors (2008) British Journal of Pharmacology, 155 (6), pp. 837-846; Peritore, A.F., Siracusa, R., Crupi, R., Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets (2019) Nutrients, 11 (9), p. 2175; Petrosino, S., Di Marzo, V., The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations (2017) British Journal of Pharmacology, 174 (11), pp. 1349-1365; Sanz-Salvador, L., Andr{\'e}s-Borderia, A., Ferrer-Montiel, A., Agonist-and Ca2+-dependent desensitization of TRPV1 channel targets the receptor to lysosomes for degradation (2012) Journal of Biological Chemistry, 287 (23), pp. 19462-19471; Simpson, D., McArthur, J.C., Dworkin, R.H., (2012) Neuropathic Pain: Mechanisms, Diagnosis, and Treatment, , New York, Oxford University Press, (eds; Skaper, S.D., Facci, L., Fusco, M., Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain (2014) Inflammopharmacology, 22 (2), pp. 79-94; Van Hecke, O., Austin, S.K., Khan, R.A., Neuropathic pain in the general population: a systematic review of epidemiological studies (2014) Pain, 155 (4), pp. 654-662",
year = "2022",
doi = "10.1177/02601060211019669",
language = "English",
volume = "28",
pages = "265--269",
journal = "Nutrition and Health",
issn = "0260-1060",
publisher = "Sage Publications Sage UK: London, England",
number = "2",
}